Allena Pharmaceuticals, Inc. [NASDAQ:ALNA]: Analyst Rating and Earnings
Experts stock market traders frequently make a point to check what top Wall Street analysts say regarding a potential buy. Regarding Allena Pharmaceuticals, Inc. [ALNA] currently, the latest Wall Street ratings we can see is from the fiscal quarter that’s going to end in December. On average, stock market experts give ALNA an Buy rating. Its stock price has been found in the range of 3.92 to 14.42. This is compared to its latest closing price of $4.46.
Wall Street analysts provide their ratings on a scale of 1 to 5, and the current average score for Allena Pharmaceuticals, Inc. [ALNA] is sitting at 1.50. This is compared to 1 month ago, when its average rating was 1.50.
Stay on the lookout for the next publication of this organization’s financial results for the quarter, which will be made public on Tue 6 Aug (In 56 Days).
Fundamental Analysis of Allena Pharmaceuticals, Inc. [ALNA]
Turning to investigate this organization’s capital structure, Allena Pharmaceuticals, Inc. [ALNA] has generated a Total Debt to Total Equity ratio of 20.18. Similarly, its Total Debt to Total Capital is 16.79, while its Total Debt to Total Assets stands at 15.30. Looking toward the future, this publicly-traded company’s Long-Term Debt to Equity is 20.18, and its Long-Term Debt to Total Capital is 16.79. This company has a healthy balance between its debt and its current holdings, suggesting it is a reliable investment due to its ability to leverage debt in an efficient way.
What about valuation? This company’s Enterprise Value to EBITDA is -1.16. Total Debt to Enterprise Value stands at 0.16. Allena Pharmaceuticals, Inc. [ALNA] has a Price to Book Ratio of 2.29.
This publicly-traded organization’s liquidity data is also interesting: its Quick Ratio is 11.19 and its Current Ratio is 11.19. This company, considering these metrics, has a healthy ratio between its short-term liquid assets and its short-term liabilities, making it a less risky investment.
Allena Pharmaceuticals, Inc. [ALNA] has 21.88M shares outstanding, amounting to a total market cap of $94.74M. Its stock price has been found in the range of 3.92 to 14.42. At its current price, it has moved by -69.97% from its 52-week high, and it has moved 10.46% from its 52-week low.
This stock’s Beta value is currently , which indicates that it is more volatile that the wider market. This stock’s Relative Strength Index (RSI) is at 40.07. This RSI score is good, suggesting this stock is neither overbought or oversold.
Conclusion: Is Allena Pharmaceuticals, Inc. [ALNA] a Reliable Buy?
Allena Pharmaceuticals, Inc. [ALNA] stock is presenting a less attractive investment opportunity when compared to similarly-sized corporations in the same industry. The price performance of these shares has not shown much promise, and the financial results that this company has recently delivered present a highly risky investment.